SCHEMBL23364641

SCHEMBL23364641

CC(=O)c1c(C)cccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.42
NOTUM Q6P988 2/20 0.41
ALDH1A1 P00352 3/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.40
ALOX12 P18054 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
RORC P51449 2/20 0.38
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
LMNA P02545 1/20 0.38
TYK2 P29597 1/20 0.38
RIPK1 Q13546 1/20 0.37
NFKB1 P19838 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932939 1.00 THRB (0.42) THRBNOTUMALDH1A1GAAKDM4E
SCHEMBL1995318 0.88 THRB (0.48) THRBNOTUMALDH1A1GAAKDM4E
SCHEMBL1505171 0.85 TDP1 (0.47) ALDH1A1GAAKDM4EATMNPSR1
SCHEMBL16888475 0.83 ALDH1A1 (0.42) NOTUMALDH1A1GAAKDM4EATM
SCHEMBL8200473 0.83 SCN9A (0.40) ALDH1A1GAAKDM4EATMNPSR1
SCHEMBL25066520 0.82 GABRA1 (0.53) THRBALDH1A1GAAKDM4EATM
SCHEMBL13519060 0.81 THRB (0.63) THRBNOTUMALDH1A1GAATDP1
SCHEMBL30313345 0.81 CES2 (0.48) THRBNOTUMTDP1MAOAMAOB
SCHEMBL716995 0.81 CES2 (0.48) THRBNOTUMTDP1MAOAMAOB
SCHEMBL9525419 0.79 TYK2 (0.54) THRBALDH1A1NPSR1RORCTYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION 2024-01-04 US disclosed
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 EP disclosed
CN-115003659-A 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity 健赞公司 2022-09-02 CN disclosed
WO-2021097057-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY CFTR, PKD2, PKD1 THRB 2830/4885NOTUM 1156/4885ALDH1A1 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.